Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes
Authors' conclusion
This study will provide mechanistic insight into how IPE influences macrophage-driven inflammation in ASCVD and T2DM, informing strategies to target residual inflammatory risk in high-risk cardiometabolic populations.
Study context
- Population
- Patients with atherosclerotic CVD (atherosclerotic cardiovascular disease (ASCVD)), stratified by T2D status, prescribed icosapent ethyl (IPE) (Vazkepa®); also healthy donors (EPA in vitro)
- Comparison
- IPE-naïve vs after 6 months of IPE therapy; in parallel, EPA-treated monocyte-derived macrophages (MDMs) from healthy donors and ASCVD patients
Methodological detailsmechanistic, stratified by T2D status, Outcomes to be evaluated: NLRP3 inflammasome priming and activation, inflammatory cytokine profiles, markers of cellular senescence
- Mechanistic
- Stratified by T2D status
- Outcomes to be evaluated: NLRP3 inflammasome priming and activation, inflammatory cytokine profiles, markers of cellular senescence
Primary result
As reported in the abstract
- Protocol; no results reported. Hypothesis: IPE attenuates NLRP3 inflammasome priming and activation in MDMs, reducing cellular inflammation and senescence
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes. Diabet Med. Published 9 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →